Search

Your search keyword '"Segelov, E."' showing total 277 results
Start Over Author "Segelov, E."
277 results on '"Segelov, E."'

1. The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer

Author

Body A, Prenen H, Latham S, Lam M, Tipping-Smith S, Raghunath A, and Segelov E

Subjects
colorectal cancer, preoperative chemotherapy, perioperative chemotherapy, staging, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Amy Body,1,2 Hans Prenen,1,3 Sarah Latham,1 Marissa Lam,1 Samuel Tipping-Smith,1 Ajay Raghunath,1 Eva Segelov1,2 1Medical Oncology, Monash Medical Centre, Clayton, Melbourne, VIC, Australia; 2School of Clinical Sciences, Monash University, Clayton, Melbourne, VIC, Australia; 3Oncology Department, University Hospital Antwerp, Antwerp, BelgiumCorrespondence: Amy BodyMonash Health Translational Precinct, Monash Medical Centre, 246 Clayton Road, Clayton, Melbourne, VIC 3168, AustraliaEmail amylouise.body@monashhealth.orgAbstract: Neoadjuvant systemic therapy has many potential advantages over up-front surgery, including tumor downstaging, early treatment of micrometastatic disease, and providing an in vivo test of tumor biology. Due to these advantages, neoadjuvant therapy is becoming the standard of care for an increasing number of tumor types. Currently, colon cancer patients are still routinely treated with up-front surgery, and neoadjuvant systemic therapy is not yet standard. Limitations to widespread use of neoadjuvant therapy have included inaccurate radiological staging, concerns about tumor progression while undergoing preoperative treatment rendering a patient incurable, and a lack of randomized data demonstrating benefit. However, there is great interest in neoadjuvant chemotherapy, and a number of trials are under way. Early follow up of the first phase III trial of neoadjuvant chemotherapy for colon cancer demonstrated tumor downstaging and suggested an improvement in disease-free survival with neoadjuvant chemotherapy, and it is hoped that this will translate into longer-term overall survival benefit. Clinicians should closely watch this developing field, consider the option of neoadjuvant chemotherapy for colon cancer patients, and actively seek out opportunities for their patients to participate in ongoing clinical trials to further inform this field in future.Keywords: colorectal cancer, preoperative chemotherapy, perioperative chemotherapy, staging

Published
2021

3. Refractory Metastatic Colorectal Cancer: Current Challenges and Future Prospects

Author

Lam M, Lum C, Latham S, Tipping Smith S, Prenen H, and Segelov E

Subjects
molecular targets, genomic profiling, immunotherapy, precision medicine, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Marissa Lam,1 Caroline Lum,1 Sarah Latham,1 Sam Tipping Smith,1 Hans Prenen,2 Eva Segelov1,3 1Department of Medical Oncology, Monash Medical Center, Clayton, Australia; 2Department of Oncology, University Hospital Antwerp, Edegem, Belgium; 3Faculty of Medicine, Monash University, Clayton, AustraliaCorrespondence: Eva Segelov Level 7 MHTP, Monash Health 246 Clayton Road, Clayton VIC 3168, AustraliaTel +613 85722392Fax +613 8572 2446Email eva.segelov@monash.eduAbstract: Despite advances, patients with metastatic colorectal cancer (mCRC) still have poor long-term survival. Identification of molecular subtypes is important to guide therapy through standard treatment pathways and holds promise for the development of new treatments. Following standard first- and second-line chemotherapy plus targeted agents, many patients retain a reasonable performance status, and thus are seeking further effective treatment to extend life and maintain symptom control. The challenge lies in selecting the most appropriate therapy in the third- and fourth-line settings, from a range of options including the relatively new oral agents TAS-102 and regorafenib, or rechallenge with previous chemotherapy or anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mAB). Beyond this, therapy consists of trials involving novel agents and new combinations of treatments with theoretical synergy and/or non-overlapping toxicity. There is a great focus on enhancing immunogenicity in mCRC, to reflect the impressive results of immunotherapy drugs in the small cohort with mismatch repair deficient (dMMR) mCRC. Rare molecular subtypes of mCRC are increasingly being identified, including Her2-positive disease, NTRK fusions and others. Clinical trials exploring the efficacy of immunomodulatory and precision agents are plentiful and will hopefully yield clinically meaningful results that can be rapidly translated into routine care.Keywords: molecular targets, genomic profiling, immunotherapy, precision medicine

Published
2020

11. 380P Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Author

Day, D., primary, Starus, A., additional, Lamik, A., additional, Sieber, O., additional, Begbie, S., additional, Bonaventura, A., additional, Rai, S., additional, Karanth, N., additional, Underhill, C.R., additional, Nott, L.M., additional, van Hazel, G., additional, van Hagen, T., additional, Wong, M., additional, Saqib, A., additional, Eastgate, M., additional, Srivastav, R., additional, Chia, J., additional, Toh, H.C., additional, Jones, F., additional, and Segelov, E., additional

Published
2022
Full Text
View/download PDF

12. 1614P Influence of cancer on COVID-19 vaccine beliefs, attitudes and uptake

Author

Nguyen, M., primary, Bain, N.T., additional, Grech, L., additional, Kwok, A., additional, Hamad, N., additional, Tognela, A., additional, Chan, B.A., additional, Nott, L.M., additional, Harris, S., additional, Chau, N.M.H., additional, Underhill, C.R., additional, Day, D., additional, McCartney, A., additional, Webber, K., additional, and Segelov, E., additional

Published
2022
Full Text
View/download PDF

13. 1611P Clinical determinants of SARS-CoV-2 vaccine response in adults with cancer

Author

Segelov, E., primary, Body, A., additional, Lal, L., additional, Abdulla, H., additional, Turville, S., additional, Naing, Z., additional, Opat, S., additional, Leahy, M., additional, Balendra, J.R., additional, Hamad, N., additional, Mccuaig, R., additional, Rao, S., additional, Lineburg, K., additional, Smith, C., additional, MacIntyre, C.R., additional, Milch, V., additional, Busija, L., additional, and Ahern, E.S., additional

Published
2022
Full Text
View/download PDF

14. COVID-19 vaccine hesitancy in Australian patients with solid organ cancers

Author

Bain, N., primary, Nguyen, M., additional, Grech, L., additional, Day, D., additional, McCartney, A., additional, Webber, K., additional, Kwok, A., additional, Harris, S., additional, Chau, H., additional, Chan, B., additional, Nott, L., additional, Hamad, N., additional, Tognela, A., additional, Underhill, C., additional, Loe, B.S., additional, Freeman, D., additional, and Segelov, E., additional

Published
2022
Full Text
View/download PDF

16. P-94 Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Author

Day, D., primary, Starus, A., additional, Sieber, O., additional, Prasse, D., additional, Lamik, A., additional, Fredebohm, J., additional, Simes, J., additional, Day, F., additional, Jeffery, M., additional, Zielinski, R., additional, Singh, M., additional, Chong, G., additional, Li, S., additional, Mouradov, D., additional, Chia, J., additional, Ali, R., additional, Toh, H., additional, Jones, F., additional, and Segelov, E., additional

Published
2022
Full Text
View/download PDF

17. TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer

Author

Ferraro, D., Goldstein, D., O’Connell, R. L., Zalcberg, J. R., Sjoquist, K. M., Tebbutt, N. C., Grimison, P., McLachlan, S., Lipton, L. L., Vasey, P., Gebski, V. J., Aiken, C., Cronk, M., Ng, S., Karapetis, C. S., Shannon, J., Shannon, J., Goldstein, D., Tebbutt, N., Ng, S., Cronk, M., Karapetis, C., Sjoquist, K., Aiken, C., Do, V., Marschner, I., Friedlander, M., Gurney, H., Simes, J., Hague, W., O’Connell, R., Gebski, V., Aiken, C., Gorzeman, M., Pike, R., Miranda, K, Waring, P., Ferraro, D., Lau, D., Fox, S., Tebbutt, N., Liu, Y., Vasey, P., Wood, T., Cronk, M., Cocks, C., Simmons, K., Shannon, J., McCourt, J., Jefford, M., Hobinchet, A., Grimison, P., Mirco, B., Sagong, J., Ng, S., Dudukovic, S., Aghmesheh, M., Parker, S., Segelov, E., Ratnayake, L., McLachlan, S., Ranieri, N., Varma, S., Page, J., Heyer, E., Abdi, E., Chorlton, C., Lipton, L., Wilkinson, L., and behalf of the the Australasian Gastro-Intestinal Trials Group

Published
2016
Full Text
View/download PDF

20. EPV003/#326 An integrated genomic, proteomic and immunopeptidomic approach to discover novel tumour neoantigens in an immunologically cold ovarian cancer for personalised T-cell receptor therapy

Author

Ho, GY, primary, Faridi, P, additional, Wu, J, additional, Barker, H, additional, Nguyen-Dumont, T, additional, Chang, J, additional, Fell, A, additional, Eggenhuizen, P, additional, Steen, J, additional, Manolitsas, T, additional, Frentzas, S, additional, Bedo, J, additional, Vandenberg, C, additional, Papenfuss, T, additional, Scott, C, additional, Ooi, J, additional, and Segelov, E, additional

Published
2021
Full Text
View/download PDF

26. 586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

Author

Day, D., Starus, A., Gebski, V., Simes, J., Hayes, T., Padinharakam, S., Strickland, A.H., Briscoe, K., Varma, S., Barnet, M., Jackson, C., Horvath, L.G., Price, T.J., Tebbutt, N., Karki, B., Diakos, C.I., Chia, J., Toh, H.C., Jones, F.S., and Segelov, E.

Published
2023
Full Text
View/download PDF

27. Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study

Author

Partelli, S. Ramage, J.K. Massironi, S. Zerbi, A. Kim, H.B. Niccoli, P. Panzuto, F. Landoni, L. Tomazic, A. Ibrahim, T. Kaltsas, G. Bertani, E. Sauvanet, A. Segelov, E. Caplin, M. Coppa, J. Armstrong, T. Weickert, M.O. Butturini, G. Staettner, S. Boesch, F. Cives, M. Moulton, C.A. He, J. Selberherr, A. Twito, O. Castaldi, A. De Angelis, C.G. Gaujoux, S. Almeamar, H. Frilling, A. Vigia, E. Wilson, C. Muffatti, F. Srirajaskanthan, R. Invernizzi, P. Lania, A. Kwon, W. Ewald, J. Rinzivillo, M. Nessi, C. Smid, L.M. Gardini, A. Tsoli, M. Picardi, E.E. Hentic, O. Croagh, D. Toumpanakis, C. Citterio, D. Ramsey, E. Mosterman, B. Regi, P. Gasteiger, S. Rossi, R.E. Smiroldo, V. Jang, J.-Y. Falconi, M.

Abstract

Introduction: The optimal treatment for small, asymptomatic, nonfunctioning pancreatic neuroendocrine neoplasms (NF-PanNEN) is still controversial. European Neuroendocrine Tumor Society (ENETS) guidelines recommend a watchful strategy for asymptomatic NF-PanNEN 18 years, the presence of asymptomatic sporadic NF-PanNEN ≤2 cm proven by a positive fine-needle aspiration (FNA) or by the presence of a measurable nodule on high-quality imaging techniques that is positive at 68Gallium DOTATOC-PET scan. Conclusion: The ASPEN study is designed to investigate if an active surveillance of asymptomatic NF-PanNEN ≤2 cm is safe as compared to surgical approach. © Copyright © 2020 Partelli, Ramage, Massironi, Zerbi, Kim, Niccoli, Panzuto, Landoni, Tomazic, Ibrahim, Kaltsas, Bertani, Sauvanet, Segelov, Caplin, Coppa, Armstrong, Weickert, Butturini, Staettner, Boesch, Cives, Moulton, He, Selberherr, Twito, Castaldi, De Angelis, Gaujoux, Almeamar, Frilling, Vigia, Wilson, Muffatti, Srirajaskanthan, Invernizzi, Lania, Kwon, Ewald, Rinzivillo, Nessi, Smid, Gardini, Tsoli, Picardi, Hentic, Croagh, Toumpanakis, Citterio, Ramsey, Mosterman, Regi, Gasteiger, Rossi, Smiroldo, Jang and Falconi.

Published
2020

32. An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours

Author

Jackson, C G C A, primary, Deva, S., additional, Bayston, K., additional, McLaren, B., additional, Barlow, P., additional, Hung, N.A., additional, Clarke, K., additional, Segelov, E., additional, Chao, T.-Y., additional, Dai, M.-S., additional, Yen, H.-T., additional, Cutler, D., additional, Kramer, D., additional, Zhi, J., additional, Chan, W.-K., additional, Kwan, M -F R, additional, and Hung, C.-T., additional

Published
2019
Full Text
View/download PDF

34. Physical Activity for Symptom Management in Women With Metastatic Breast Cancer: A Randomized Feasibility Trial on Physical Activity and Breast Metastases

Author

Yee, J, Davis, GM, Hackett, D, Beith, JM, Wilcken, N, Currow, D, Emery, J, Phillips, J, Martin, A, Hui, R, Harrison, M, Segelov, E, and Kilbreath, SL

Subjects
Anesthesiology
Abstract

© 2019 American Academy of Hospice and Palliative Medicine Context: Physical activity for women with early-stage breast cancer is well recognized for managing cancer-related symptoms and improving quality of life. While typically excluded from interventions, women with metastatic breast cancer may also benefit from physical activity. Objective: To 1) determine the safety and feasibility of a physical activity program for women with metastatic breast cancer and 2) explore the efficacy of the program. Methods: Fourteen women with metastatic breast cancer were randomized to either a control group or an 8-week home-based physical activity intervention comprising twice weekly supervised resistance training and an unsupervized walking program. Results: The recruitment rate was 93%. Adherence to the resistance and walking components of the program was 100% and 25%, respectively. No adverse events were reported. When mean change scores from baseline to postintervention were compared, trends in favor of the exercise group over the control group were observed for the Functional Assessment of Chronic Illness Therapy-Fatigue score (+5.6 ± 3.2 vs. −1.8 ± 3.9, respectively), VO2max (+1.6 ml/kg/minute ±1.8 mL/kg/minute vs. −0.2 mL/kg/minute ±0.1 mL/kg/minute, respectively) and six-minute walk test (+40 m ± 23 m vs. −46 m ± 56 m, respectively). Conclusion: A partially supervised home-based physical activity program for women with metastatic breast cancer is feasible and safe. The dose of the resistance training component was well tolerated and achievable in this population. In contrast, adherence and compliance to the walking program were poor. Preliminary data suggest a physical activity program, comprising predominantly resistance training, may lead to improvements in physical capacity and may help women to live well with their disease.

Published
2019

35. Supportive oncofertility care, psychological health and reproductive concerns: a qualitative study

Author

Wang, Y, Logan, S, Stern, K, Wakefield, CE, Cohn, RJ, Agresta, F, Jayasinghe, Y, Deans, R, Segelov, E, McLachlan, RI, Gerstl, B, Sullivan, E, Ledger, WE, and Anazodo, A

Subjects
Adult, Male, Adolescent, Australia, Psychosocial Support Systems, Fertility Preservation, Young Adult, Mental Health, Fertility, Neoplasms, Infertility, Quality of Life, Humans, Female, Oncology & Carcinogenesis, Survivors, Qualitative Research, New Zealand
Abstract

© 2019, Springer-Verlag GmbH Germany, part of Springer Nature. Purpose: Impaired fertility in cancer patients and survivors of reproductive age (15–45 years) may lead to psychological distress and poor mental health outcomes, and may negatively impact quality of life. Limited research has focused on the fertility experiences of those who have had access to supportive oncofertility care. This study aims to explore the fertility-care experiences and reproductive concerns of reproductive age cancer patients at the time of their cancer diagnosis who have had access to oncofertility care. Methods: The qualitative data from a larger mixed method study is presented, comprising 30 semi-structured telephone interviews with newly diagnosed cancer patients across Australia and New Zealand, undertaken between April 2016 and April 2018. Results: Interviews were undertaken with 9 male patients and 21 female patients aged between 15 and 44 years. All patients recalled a discussion about fertility and majority underwent some form of fertility preservation. Thematic analysis identified five main themes: (i) satisfaction with oncofertility care, (ii) a need for individualised treatment and support, (iii) desire for parenthood, (iv) fertility treatment can be challenging, and (v) fertility preservation provides a safety net for the future. Conclusions: Participants who access supportive oncofertility care report low emotional impact of threatened future infertility at the time of cancer diagnosis. These results suggest that such services may assist in lowering the emotional burden of potential infertility in survivors. Long-term research is needed to assess the longitudinal benefits for different models of care.

Published
2019

37. Supportive oncofertility care, psychological health and reproductive concerns: a qualitative study

Author

Wang, Y., primary, Logan, Shanna, additional, Stern, K., additional, Wakefield, C. E., additional, Cohn, R. J., additional, Agresta, F., additional, Jayasinghe, Y., additional, Deans, R., additional, Segelov, E., additional, McLachlan, R. I., additional, Gerstl, B., additional, Sullivan, E., additional, Ledger, W. E., additional, and Anazodo, A., additional

Published
2019
Full Text
View/download PDF

38. P1.12-06 Pulmonary Neuroendocrine (Carcinoid) Tumors: CommNETs/NANETS Endorsement and Update of the ENETs Best Practice Consensus

Author

Singh, S., primary, Bergsland, E., additional, Card, C., additional, Hope, T., additional, Kunz, P., additional, Laidley, D., additional, Lawrence, B., additional, Leyden, S., additional, Michael, M., additional, Modahl, L., additional, Myrehaug, S., additional, Padda, S., additional, Pommier, R., additional, Ramirez, R., additional, Soulen, M., additional, Strosberg, J., additional, Thawer, A., additional, Wei, B., additional, Xu, B., additional, and Segelov, E., additional

Published
2018
Full Text
View/download PDF

39. InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial

Author

Rao, S., primary, Sclafani, F., additional, Eng, C., additional, Grønlie Guren, M., additional, Adams, R.A., additional, Benson, A., additional, Sebag-Montefiore, D., additional, Segelov, E., additional, Bryant, A., additional, Peckitt, C., additional, Roy, A., additional, Seymour, M.T., additional, Welch, J., additional, Saunders, M.P., additional, Muirhead, R., additional, Bridgewater, J., additional, Falk, S., additional, Glynne-Jones, R., additional, Arnold, D., additional, and Cunningham, D., additional

Published
2018
Full Text
View/download PDF

40. The commonwealth neuroendocrine tumour collaboration (CommNETs) and North American neuroendocrine tumor society (NANETS) endorsement and update of European neuroendocrine tumor society (ENETS) best practice consensus for lung neuroendocrine tumors (LNET)

Author

Segelov, E., primary, Bergsland, E., additional, Card, C., additional, Hope, T., additional, Kunz, P., additional, Laidley, D., additional, Lawrence, B., additional, Leyden, S., additional, Michael, M., additional, Modahl, L., additional, Myrehaug, S., additional, Padda, S., additional, Pommier, R., additional, Ramirez, R., additional, Soulen, M., additional, Strosberg, J., additional, Thawer, A., additional, Wei, B., additional, and Singh, S., additional

Published
2018
Full Text
View/download PDF

41. The impact and indications for Oncotype DX on adjuvant treatment recommendations when third-party funding is unavailable

Author

Chin-Lenn, L., primary, De Boer, R. H., additional, Segelov, E., additional, Marx, G. M., additional, Hughes, T. M., additional, McCarthy, N. J., additional, White, S. C., additional, Foo, S. S., additional, Rutovitz, J. J., additional, Della-Fiorentina, S., additional, Jennens, R., additional, Antill, Y. C., additional, Tsoi, D., additional, Cronk, M. F., additional, Lombard, J. M., additional, Kiely, B. E., additional, Chirgwin, J. H., additional, Gorelik, A., additional, and Mann, G. B., additional

Published
2018
Full Text
View/download PDF

48. 417P Availability and Utility of Functional Imaging (FI) and Peptide Receptor Radionuclide Therapy (PRRT) in the CommNETS Collaboration (Australia, Canada and New Zealand)

Author

Chan, B.A., primary, Sim, H-W., additional, Ravikumar, A., additional, Bailey, D., additional, Chan, D., additional, Lawrence, B., additional, McEwan, A., additional, Pavlakis, N., additional, Segelov, E., additional, Singh, S., additional, Roach, P., additional, and Wyld, D., additional

Published
2016
Full Text
View/download PDF

49. 198P Use of chemotherapy and mismatch repair deficiency testing in resected stage II colon cancer

Author

Au, L., primary, Grant, M., additional, Haydon, A., additional, Oliva, K., additional, Wilkins, S., additional, Segelov, E., additional, Antill, Y., additional, Peter, C., additional, Ranchod, P., additional, Polglase, A., additional, Chin, M., additional, Chip, F., additional, Skinner, S., additional, Roger, W., additional, McMurrick, P., additional, and Shapiro, J., additional

Published
2016
Full Text
View/download PDF

50. LBA21 - InterAACT: A multicentre open label randomised phase II advanced anal cancer trial of cisplatin (CDDP) plus 5-fluorouracil (5-FU) vs carboplatin (C) plus weekly paclitaxel (P) in patients (pts) with inoperable locally recurrent (ILR) or metastatic treatment naïve disease - An International Rare Cancers Initiative (IRCI) trial

Author

Rao, S., Sclafani, F., Eng, C., Grønlie Guren, M., Adams, R.A., Benson, A., Sebag-Montefiore, D., Segelov, E., Bryant, A., Peckitt, C., Roy, A., Seymour, M.T., Welch, J., Saunders, M.P., Muirhead, R., Bridgewater, J., Falk, S., Glynne-Jones, R., Arnold, D., and Cunningham, D.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results